Multi-stakeholder platform to improve clinical trials in the EU – Public consultation
As part of the Accelerating Clinical Trials in the EU (ACT EU) initiative, the European Medicines Agency (EMA), the Heads of Medicines Agencies (HMA) and the European Commission (EC) are establishing a multi-stakeholder platform to improve clinical trials in the European Union (EU). The multi-stakeholder platform will support discussions across the clinical research landscape and facilitate the evolution of clinical trial methods and approaches.
To accelerate the development of safe and efficient medicines of high quality through clinical trials in the EU, the European Medicines Agency (EMA), the Heads of Medicines Agencies (HMA) and the European Commission (EC) have launched the Accelerating Clinical Trials in the EU (ACT EU) initiative.
This initiative will require the necessary collaboration, harmonization and inputs from many different stakeholders across all EU Member States. Therefore, a multi-stakeholder platform is being formed with representatives from all aspects of the EU clinical trials environment.
The establishment of a multi-stakeholder platform to improve clinical trials in the European Union (EU) will be subject to a public consultation from 3 February 2023 to 3 March 2023. Stakeholders are invited to send their comments on the ACT EU multi-stakeholder platform concept paper, advise on the key priorities for discussion and express their interest to join the platform via an online form.
Read more about the public consultation here